Navigation Links
Intradigm Closes Final Tranche of $21.4 Million Series B Financing
Date:1/7/2009

PALO ALTO, Calif., Jan. 7 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the company has closed the final tranche of its Series B financing. Astellas Venture Management led the $2.9 million tranche, with existing investor, Lilly Ventures, also participating. The addition of these funds brings the total Series B financing to $21.4 million. Intradigm will use Series B funds to advance its RNAi therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.

"Intradigm's uniquely comprehensive approach to developing RNAi therapeutics, which encompasses safe and effective delivery, proprietary siRNA sequences and novel structural features for RNAi molecules, makes the company an attractive investment in the rapidly growing RNAi space," said Shinja Yano, Ph.D., president and chief executive officer, Astellas Venture Management LLC. "We are excited to join Intradigm's group of investors and look forward to contributing to the company's future success in recognizing the substantial promise of RNAi as a therapeutic class."

Intradigm today also provided an update on recent corporate developments, announcing that Mohammad Azab, M.D., has resigned his position as chief executive officer but will retain his position on Intradigm's board of directors. Dr. Azab will be succeeded as chief executive officer by Philip Haworth, Ph.D., who previously served as the company's vice president of business development.

"The board would like to thank Dr. Azab for his valuable contributions to building the company and successfully raising the recent Series B financing. We are delighted that he will continue his strategic role on Intradigm's board," said J
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... new method of building materials using light, developed by ... enable technologies that are often considered the realm of ... , Although cloaked starships won,t be a reality ... developed for constructing materials with building blocks a few ... control the way that light flies through them, and ...
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... BRISBANE, Calif. , July 28, 2014  InterMune, ... it will release its second quarter 2014 financial results ... August 6, 2014. A live conference call and webcast will ... that same day. Interested investors and others ... (U.S.) or +1 212-231-2900 (international), conference ID#21728775. A replay of ...
Breaking Biology Technology:Building 'invisible' materials with light 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2
... ... France , January 20 Bioamber,( http://www.bio-amber.com/ ... Green Technology and France -based ARD,( http://www.a-r-d.fr/ )(Agro-industrie Recherches ... first,bio-based succinic acid plant. Since December 2009 , the ...
... ... latest product offering, PrescriberPRO Mobile. ,PrescriberPRO Mobile is a state-of-the-art smart phone ... 1,000,000 medical prescribers. The application will provide names, addresses, and other account information ... ...
... New features make ... summarizes environment and shows how it compares to industry averages. , ... (PRWEB) January 20, 2010 -- VKernel proudly announces our ... easier to manage VM sprawl, re-size VMs to improve performance and increase the number of ...
Cached Biology Technology:Bioamber Commissions World's First Renewable Succinic Acid Plant 2Bioamber Commissions World's First Renewable Succinic Acid Plant 3Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 2Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 3VKernel Releases Optimization Pack 1.2 2
(Date:7/28/2014)... help advance the genetic engineering of "fuel" crops ... developed by researchers with the U.S. Department of ... partnership led by Lawrence Berkeley National Laboratory (Berkeley ... that enables scientists to identify and characterize the ... the biosynthesis of plant cell walls. , "Our ...
(Date:7/28/2014)... virus killers to prevent and treat HIV infection has ... response these molecules can arouse as they get rid ... at the Weizmann Institute and the National Institutes of ... these molecules interferons around the time of ... the disease. Their research appeared in Nature . ...
(Date:7/28/2014)... for Biologically Inspired Engineering at Harvard University today ... commercialized by a newly formed private company to ... medicine products. The announcement follows a ... Development (OTD) and the start-up Emulate Inc., relating ... Organs-on-Chips platform. , "This is a big ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Interfering with interferon 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
... BATON ROUGE LSU,s Sibel Bargu, along with her former ... Coastal Sciences in LSU,s School of the Coast & Environment, ... open ocean for the first time. The recent findings were ... most prestigious scientific journals, the Proceedings of the National ...
... A new field study confirms that an invasive ... grass species, suggesting it will continue to spread across ... millions of acres of grazing land almost worthless. ... the Agricultural Research Service, was one of the most ...
... -- (Nov. 11, 2010) -- Future computers may run a ... graphene at Rice University. Rice researchers have learned to ... from plain table sugar and other carbon-based substances. They do ... make graphene easy to manufacture. The lab of ...
Cached Biology News:LSU oceanography researcher discovers toxic algae in open water 2LSU oceanography researcher discovers toxic algae in open water 3Invading weed threatens devastation to western rangelands 2Invading weed threatens devastation to western rangelands 3Sugar and slice make graphene real nice 2
CASPR (H-66)...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Human SIGIRR MAb (Clone 162201)...
... EPS 1001 Power Supply, 1. 1000 ... voltage, constant current, and constant power ... for precision and reproducibility.Stores and recalls ... flatbed gels on Multiphor II ...
Biology Products: